2.28

6.56% -0.16

Moleculin Biotech Inc (MBRX)

Panoramica Notizia Cronologia dei prezzi Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$2.44

Aprire:

$2.43

Volume 24 ore:

138.26K

Relative Volume:

0.29

Capitalizzazione di mercato:

$16.11M

Reddito:

Utile/perdita netta:

$-30.33M

Rapporto P/E:

-0.0813

EPS:

-28.0369

Flusso di cassa netto:

$-24.28M

1 W Prestazione:

-13.64%

1M Prestazione:

-8.80%

6M Prestazione:

-42.71%

1 anno Prestazione:

-82.92%

Intervallo 1D:

$2.25

$2.43

Intervallo di 1 settimana:

$2.19

$2.6499

Portata 52W:

$1.79

$24.00

Moleculin Biotech Inc Stock (MBRX) Company Profile

Nome

Moleculin Biotech Inc

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

713-300-5160

Indirizzo

5300 MEMORIAL DRIVE, HOUSTON, TX

Dipendente

Cinguettio

@moleculinbio

Prossima data di guadagno

2026-08-11

Ultimi documenti SEC

MBRX's Discussions on Twitter

Compare MBRX vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
MBRX Moleculin Biotech Inc	2.28	16.11M	0	-30.33M	-24.28M	-28.04
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-09	Ripresa	H.C. Wainwright	Buy
2025-02-12	Downgrade	Maxim Group	Buy → Hold
2022-07-18	Ripresa	Oppenheimer	Outperform

Moleculin Biotech Inc Borsa (MBRX) Ultime notizie

Jul 11, 2026

Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView

Jul 11, 2026

Jul 09, 2026

Enterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView

Jul 09, 2026

Jul 07, 2026

Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView

Jul 07, 2026

Why Did MBRX Stock Climb 14% Today? - Stocktwits

Jul 07, 2026

Moleculin Biotech focuses on oncology pipeline and Nasdaq listing - ad-hoc-news.de

Jul 07, 2026

Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment - marketscreener.com

Jul 07, 2026

Jul 06, 2026

Moleculin CEO discusses preliminary results from leukemia trial By Investing.com - Investing.com Australia

Jul 06, 2026

Moleculin CEO discusses preliminary results from leukemia trial - Investing.com

Jul 06, 2026

Moleculin reports positive early results from P... - Pluang

Jul 06, 2026

Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment - Quiver Quantitative

Jul 06, 2026

Moleculin says early MIRACLE trial data support Annamycin in leukemia - Stock Titan

Jul 06, 2026

Jul 05, 2026

Moleculin Biotech | 8-K: Current report - Moomoo

Jul 05, 2026

Jul 04, 2026

MBRXMoleculin Biotech Inc Dividends - Finviz

Jul 04, 2026

Jul 02, 2026

Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Jul 02, 2026

Jul 01, 2026

What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI

Jul 01, 2026

Jun 30, 2026

Why is Moleculin stock falling today? - MSN

Jun 30, 2026

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - Asianet Newsable

Jun 30, 2026

Moleculin Biotech, Inc. Financial Disclosures & Filings - TradingView

Jun 30, 2026

Why is Moleculin Stock Falling Today? - Benzinga

Jun 30, 2026

H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo

Jun 30, 2026

Moleculin Biotech (MBRX) Reports Positive Efficacy Results in Ph - GuruFocus

Jun 30, 2026

Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data. - Bitget

Jun 30, 2026

Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates - Minichart

Jun 30, 2026

Moleculin reports positive interim data from AML trial By Investing.com - Investing.com India

Jun 30, 2026

Form 8-K Moleculin Biotech, Inc. For: Jun 30 - StreetInsider

Jun 30, 2026

Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim - Stock Titan

Jun 30, 2026

Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised - Stock Titan

Jun 30, 2026

Moleculin Reports Positive Phase 2/3 MIRACLE Interim - GlobeNewswire

Jun 30, 2026

Jun 26, 2026

MBRX Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Moleculin Biotech, Inc. Actuals & Estimates (MUN:MOL0) - TradingView

Jun 26, 2026

Jun 25, 2026

Moleculin Biotech, Inc. Actuals & Estimates (LSE:0K2H) - TradingView

Jun 25, 2026

0K2H Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Form 4 Moleculin Biotech Inc For: 24 June By Investing.com - Investing.com Nigeria

Jun 25, 2026

Jun 24, 2026

Moleculin Biotech (MBRX) CEO reports RSU vesting, tax-share withholding and retained stake - Stock Titan

Jun 24, 2026

Moleculin Biotech (MBRX) CSO exercises RSUs with tax withholding, increases common stock stake - Stock Titan

Jun 24, 2026

Moleculin Biotech | 4: Statement of changes in beneficial ownership of securities-Officer PICKER DONALD H - Moomoo

Jun 24, 2026

Jun 23, 2026

MBRX Stock Whipsaws As Traders Focus On Cash Runway - StocksToTrade

Jun 23, 2026

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits

Jun 23, 2026

MBRX Stock Draws Trader Focus As Volatility Spikes - timothysykes.com

Jun 23, 2026

$Moleculin Biotech (MBRX.US)$ - Moomoo

Jun 23, 2026

Trending Stocks Today | Moleculin Biotech Shoots up 106.41% Pre-Market - Moomoo

Jun 23, 2026

Jun 22, 2026